Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk

Recruiting Phase 4 Interventional Study
Venous Thromboembolism (VTE) Post Partum Women
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
2,400 (estimated)
Sponsor
University Hospital, Brest · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4/1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths. Majority of postpartum VTE occurs in women with one or more moderate risk factors (obesity, caesarean section, post…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Women at intermediate risk of VTE during post-partum= with a 3% or more risk of VTE based on a validated prediction model\* or International guidelines (ACCP 2012). * Age over 18 years * Delivery between 6 hours and \< 36 hours * Written informed consent * Definition: Inter…
Contacts

Emmanuelle LE MOIGNE, MD, PhD

0298347344

emmanuelle.lemoigne@chu-brest.fr

CONTACT

Sarah ROBIN, MD

sarah.robin@chu-brest.fr

CONTACT